** Brokerage Jefferies starts coverage on ophthalmic medical device company Rxsight RXST.O with "buy" rating and sets PT at $50
** New PT more than double the stock's last close
** Brokerage says RXST's competitive moat is strong, with significant growth potential and minimal competition expected in the next 5 years
** Sees upside in the company's light adjustable lenses (LALs) used in cataract surgery; says the procedure is highly profitable for surgeons
** LALs allow post-implantation adjustments unlike traditional lenses
** 8 out of 10 brokerages rate the stock "buy" or higher, 2 rate "hold" and median PT is $43 - LSEG data
** RXST stock down 51% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。